Cardiac Prosthetic Devices Market By Product Type (Prosthetic Heart Valves [Mechanical Heart Valves, Bioprosthetic Heart Valves, Transcatheter Aortic Heart Valves, Transcatheter Mitral Heart Valves, Polymeric Heart Valves], Cardiac Pacemakers [Single-Chamber Pacemakers, Dual-Chamber Pacemakers, Biventricular Pacemakers, Leadless Pacemakers, Pacemaker Generators]); By Application (Aortic Stenosis, Aortic Regurgitation, Mitral Regurgitation, Mitral Stenosis, Bradyarrhythmias, Cardiac Conduction Disorders, Valve-in-Valve Replacement, Pacemaker Generator Replacement); By Procedure Type (Open Surgical Implantation, Transcatheter Implantation, Minimally Invasive Surgical Implantation, Replacement and Revision Procedures); By End User (Hospitals, Cardiac Surgery Centers, Structural Heart and Catheterization Centers, Electrophysiology Laboratories, Specialty Cardiology Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Cardiac Prosthetic Devices Market: Transcatheter Valve Expansion and Replacement Demand Reshape the Revenue Base

The Global Cardiac Prosthetic Devices Market is projected to grow from USD 10.68 billion in 2025 to USD 19.53 billion by 2032, expanding at a CAGR of 9.0%, according to Strategic Market Research.

 

The cardiac prosthetic devices market is increasingly defined by completed implantation procedures rather than broad disease prevalence. Hospitals generate demand when patients receive surgical or transcatheter heart valves, conventional or leadless pacemakers, replacement generators, and revision procedures. For analytical consistency, the market includes prosthetic heart valves and permanent pacing systems while excluding coronary stents, implantable cardioverter-defibrillators, ventricular-assist devices, artificial hearts, and repair-only products.

 

The disease pool remains large enough to sustain long-term procedural demand. A 2024 Global Burden of Disease analysis estimated that 54.8 million people were living with rheumatic heart disease in 2021, alongside 13.3 million with calcific aortic valve disease and 15.5 million with degenerative mitral valve disease. These categories represent a combined burden of approximately 83.6 million people, but only a fraction become eligible for implantation after diagnosis, imaging, anatomical assessment, surgical-risk review, and payer authorization. Pacemakers are included because the Centers for Medicare & Medicaid Services classifies permanent cardiac pacemakers under the prosthetic-device benefit category.

 

U.S. TAVR Volume Establishes the Largest Verified Treatment Base

The STS/ACC TVT Registry recorded 383,030 U.S. patients who underwent transcatheter aortic valve replacement for severe aortic stenosis between January 2020 and March 2024. Among them, 108,407 were considered clinically low risk by treating teams, while 42,093 would have met the narrower eligibility criteria used in earlier low-risk trials. Real-world adoption has therefore moved beyond the highly selected populations that supported the first approvals.

Heart-team assessment, anatomical suitability, hospital accreditation, procedural scheduling, and payer rules still determine whether an identified patient reaches implantation. Manufacturers with strong physician-training, registry-support, and reimbursement capabilities are better positioned to convert a growing clinically eligible population into completed procedures.

TAVR had already overtaken surgical aortic valve replacement in the United States by 2019, when 72,991 transcatheter procedures were performed compared with 57,626 surgical replacements. Surgical valves continue to represent substantial demand when complex anatomy, concurrent cardiac surgery, age, infection, or lifetime treatment planning favors open replacement.

The United Kingdom shows the same change in procedure mix. National Cardiac Audit Programme data indicate that the number of patients treated for aortic valve disease rose 1.9 times over ten years, while TAVI activity increased fivefold and surgical aortic valve replacement declined 26%. Open surgery lost procedure share, but the overall treated population expanded. Suppliers with both surgical and transcatheter portfolios can retain hospital relationships as treatment decisions shift between the two routes.

 

Transcatheter Aortic Valves Hold the Largest Premium Revenue Position

Edwards Lifesciences generated USD 4.5 billion in global TAVR sales during 2025, representing constant-currency growth of 8.6%. The company also reported stable global average pricing and competitive position. TAVR combines large procedure volumes with stronger pricing resilience than many mature cardiovascular-device categories.

Edwards’ surgical structural-heart sales exceeded USD 1 billion in 2025 and grew 4% at constant currency. Hospitals still require open replacement for patients with multivalve disease, concomitant bypass surgery, endocarditis, or anatomy unsuitable for catheter-based treatment. Suppliers offering surgical valves, TAVR systems, mitral technologies, procedural support, and reintervention options are less exposed when clinical practice shifts between treatment routes.

Earlier intervention may enlarge the U.S. addressable population. The FDA expanded the indication for Edwards’ SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA systems in April 2025 to include selected patients with asymptomatic severe aortic stenosis. Treating patients before symptom-led deterioration could support additional procedures, but reimbursement policy will determine the rate of routine adoption.

 

Medicare Policy Directly Shapes U.S. TAVR Access

Current Medicare coverage links TAVR payment to an FDA-approved complete valve system, multidisciplinary heart-team care, qualified hospital infrastructure, and registry participation. Manufacturers must help hospitals train physicians, maintain program qualifications, document outcomes, and manage payer requirements rather than relying on regulatory approval alone.

CMS released a proposed TAVR decision memorandum on June 15, 2026. The proposal would remove Coverage with Evidence Development requirements for symptomatic severe aortic stenosis, add asymptomatic severe disease under evidence-development coverage, and revise hospital and operator criteria. Proposed operator thresholds include at least 20 transcatheter valve procedures annually, including 15 TAVR procedures, or 40 procedures over two years, including 30 TAVR cases.

The proposal was not final as of July 16, 2026, with CMS listing September 13, 2026, as the expected completion date. Finalization could lower administrative barriers for symptomatic patients, create a reimbursement route for asymptomatic treatment, and change the economics of smaller structural-heart programs.

 

Mitral Replacement, Native Aortic Regurgitation, and Next-Generation Valves Expand the Pipeline

Transcatheter mitral valve replacement is entering the U.S. commercial market after years of restricted clinical development. The FDA approved Edwards’ SAPIEN M3 system in December 2025 for selected patients with moderate-to-severe or severe mitral regurgitation who are unsuitable for surgery or transcatheter edge-to-edge repair. Abbott received U.S. approval for Tendyne in May 2025 for selected patients with severe mitral annular calcification who were unsuitable for surgery or mitral repair. Both systems address high-acuity patients with limited alternatives, supporting premium positioning while concentrating initial use in specialist centers.

JenaValve secured FDA approval for the Trilogy Transcatheter Heart Valve System in March 2026 for symptomatic severe native aortic regurgitation in patients at high or greater surgical risk. The indication gives JenaValve a differentiated position outside the calcific aortic-stenosis market that has historically driven conventional TAVR volume.

Medtronic’s Intrepid TMVR system remains investigational and is being evaluated through the APOLLO trial. The transfemoral version is intended to move mitral replacement away from more invasive access while broadening the anatomies that can be treated. Commercial timing remains uncertain because Intrepid is not approved for sale in any country.

Meril Life Sciences is advancing the Myval family through its newer Octacor and Octapro designs. The Myval Octapro uses a low-profile delivery system, a broad size matrix, and design changes intended to improve positioning and coronary access while limiting paravalvular leakage. The system has been introduced in parts of Europe but is not approved for sale in the United States, so its near-term commercial contribution will remain concentrated in selected international markets.

 

Polymeric and Regenerative Valves Target the Durability–Anticoagulation Trade-Off

Mechanical valves provide long durability but generally require lifelong anticoagulation, while tissue valves avoid long-term warfarin in many patients but can calcify or deteriorate and require another procedure. Polymeric valves are being developed to narrow that trade-off by combining durable synthetic materials with blood-contact characteristics closer to tissue valves.

Foldax’s TRIA platform uses its LifePolymer material and has reached clinical use in India for mitral replacement, while the mitral valve remains investigational in the United States. One-year Indian clinical data provide an early human evidence base, but claims that polymeric valves will eliminate anticoagulation or last for life remain development goals rather than established outcomes. Successful long-term evidence could open a new material category and reduce dependence on animal tissue, mechanical carbon components, and repeat replacement procedures.

Regenerative valves remain earlier in development. Georgia Tech researchers reported a 3D-printed, bioresorbable valve prototype in 2025 that can be folded for catheter delivery and is designed to be absorbed as the patient’s own tissue forms around the scaffold. Benchtop and durability testing are still underway. Commercial value would be greatest in pediatric and younger patients who currently face multiple replacements because existing implants do not grow with the body, but regulatory translation will require extensive preclinical and human evidence.

 

Pacemaker Revenue Is Moving Toward Replacement and Leadless Systems

Pacemakers follow a different revenue pattern from prosthetic valves. UK pacemaker activity declined 12% between 2015/16 and 2023/24, but generator changes increased 26%. Hospitals therefore need replacement forecasting, inventory continuity, compatibility planning, and long-term patient follow-up. Manufacturers benefit when programming systems, remote monitoring, physician familiarity, and replacement compatibility keep hospitals within the same product family.

Leadless pacing provides a growth route within this mature installed-base business. Medtronic reported 17% growth in Cardiac Rhythm & Heart Failure revenue during fiscal 2026 and identified Micra leadless pacemakers as a contributor. Abbott reported second-quarter 2025 rhythm-management sales of USD 673 million, with organic growth of 9.8%, and cited the AVEIR platform among the products supporting performance.

Dual-chamber leadless pacing has moved beyond the trial-only stage. The FDA approved Abbott’s AVEIR DR system in June 2023, using separate right-atrial and right-ventricular devices that communicate to coordinate pacing without conventional transvenous leads. An ongoing post-approval study is assessing long-term safety in real-world use. Medicare coverage for leadless systems remains tied to evidence-development conditions, adding registry, documentation, and follow-up requirements to the commercial pathway.

 

Complication Risk Influences Device Choice and Lifetime Cost

Thrombosis, bleeding, infection, hemolysis, paravalvular leakage, conduction disturbances, tissue overgrowth, and structural deterioration affect hospital purchasing and physician choice. Mechanical-valve recipients commonly require long-term anticoagulation, creating a continuing bleeding-management burden, while bioprosthetic valves can wear out or calcify and generate repeat surgery or valve-in-valve demand. Antibiotics, anticoagulants, antiplatelet medicines, diuretics, and anemia treatment support patients before or after implantation but form separate pharmaceutical markets.

Among clinically designated low-risk TAVR patients in the STS/ACC analysis, 8.4% required a new pacemaker within 30 days. These implantations generate additional pacing demand but also raise the total cost of TAVR and can affect physician preference between valve platforms.

The FDA reported a potentially higher cumulative incidence of structural valve deterioration within five years for Abbott’s Trifecta and Trifecta GT surgical valves compared with other surgical bioprostheses. Abbott stopped U.S. sales and distribution in July 2023. Hospitals now place greater weight on long-term durability evidence, coronary access, compatibility with later intervention, and the feasibility of valve-in-valve treatment.

 

Competition Is Concentrating Around Complete Hospital Pathways

Edwards holds the strongest dedicated structural-heart position through its TAVR scale, surgical valve business, and expanding mitral and tricuspid portfolio. Medtronic and Abbott compete across valves, pacing, rhythm management, procedural support, and long-term follow-up. Boston Scientific and Biotronik add competition in conventional pacing, while specialist and regional manufacturers compete through focused valve portfolios and local hospital relationships. Meril has developed a broader international position through its Myval transcatheter valve family.

Hospital purchasing decisions extend beyond implant price. Structural-heart and electrophysiology programs evaluate clinical evidence, physician training, procedural support, inventory reliability, reimbursement assistance, manufacturing capacity, post-market commitments, remote monitoring, and compatibility with future replacement or revision.

North America has the strongest verified combination of procedure volumes, regulatory approvals, manufacturer revenue, registry infrastructure, and reimbursement activity. The United Kingdom provides clear evidence of longer-term treatment migration: TAVI volume has increased sharply, surgical AVR has lost share, and pacemaker generator replacement has expanded despite lower total pacing activity.

 

Market Outlook

Transcatheter treatment of asymptomatic aortic stenosis, mitral valve replacement, native aortic-regurgitation replacement, leadless pacing, generator replacement, and valve-in-valve procedures offer the strongest expansion routes. Polymeric and regenerative valves could create new material categories, but their commercial contribution will depend on long-term durability, thrombogenicity, manufacturing consistency, and regulatory evidence.

Revenue growth will depend on regulatory approval, payer coverage, patient identification, hospital qualification, specialist capacity, and long-term outcomes progressing together. The projected increase from USD 10.68 billion in 2025 to USD 19.53 billion by 2032 reflects rising transcatheter adoption, entry into additional valve indications, leadless pacing growth, and recurring replacement demand from the expanding installed device base.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 10.68 Billion
Revenue Forecast in 2032	USD 19.53 Billion
Overall Growth Rate	CAGR of 9.0% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Billion, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By Procedure Type, By End User, By Geography
By Product Type	Prosthetic Heart Valves [Mechanical Heart Valves, Bioprosthetic Heart Valves, Transcatheter Aortic Heart Valves, Transcatheter Mitral Heart Valves, Polymeric Heart Valves], Cardiac Pacemakers [Single-Chamber Pacemakers, Dual-Chamber Pacemakers, Biventricular Pacemakers, Leadless Pacemakers, Pacemaker Generators]
By Application	Aortic Stenosis, Aortic Regurgitation, Mitral Regurgitation, Mitral Stenosis, Bradyarrhythmias, Cardiac Conduction Disorders, Valve-in-Valve Replacement, Pacemaker Generator Replacement
By Procedure Type	Open Surgical Implantation, Transcatheter Implantation, Minimally Invasive Surgical Implantation, Replacement and Revision Procedures
By End User	Hospitals, Cardiac Surgery Centers, Structural Heart and Catheterization Centers, Electrophysiology Laboratories, Specialty Cardiology Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, UAE, South Africa
Market Drivers	Rising structural heart disease burden, growing adoption of transcatheter valve replacement, increasing pacemaker implantation for bradyarrhythmias and conduction disorders, expanding minimally invasive cardiac procedures, and higher replacement demand among aging patients
Customization Option	Available upon request